Pfizer developed Palbonix (Palbociclib), sold under the brand name Ibrance among others, for the treatment of HR-positive and HER2-negative breast cancer. Beacon Pharmaceuticals manufactures this medicine.
Frequently Asked Questions About Palbonix (Palbociclib)
Q: What is Palbonix (Palbociclib)?
Palbonix (Palbociclib) is a targeted or biological therapy drug. Patients take Palbonix alongside hormone (endocrine) therapy to treat breast cancer. The drug’s non-branded name is Palbociclib. Its brand name is Ibrance. It belongs to a group of drugs called CDK (cyclin-dependent kinase) inhibitors.
Q: How does Palbonix 125 mg Work?
Palbonix 125 mg works by blocking these proteins, helping to stop the cancer cells from growing and dividing. When combined with hormone therapies that block the effects of estrogen on cancer cells, palbociclib helps to delay the growth of ER+, HER2-negative breast cancer. for more information visit
Q: What happens if I miss a dose of Palbonix?
If you miss a palbociclib dose or are sick (vomit) soon after taking it, do not take an extra dose to make up for the one you missed. Keep to your usual amount and speak to someone in your treatment team.
Dosage & Administration:
Patients should take a 125 mg capsule of Palbonix orally once daily for 21 consecutive days, followed by 7 days of no treatment, to complete a 28-day cycle. Administer the recommended dose of an aromatase inhibitor when given with Palbonix 125 mg (Palbociclib). Refer to the Full Prescribing Information for aromatase inhibitor therapy to ensure safe and effective use. When given with (Palbociclib), the recommended dose of fulvestrant is 500 mg administered on Days 1,15, 29, and once monthly thereafter. Please refer to the Full Prescribing Information of fulvestrant. Pre/perimenopausal women treated with the combination of palbocent 125 mg (Palbociclib) plus fulvestrant therapy should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.
Overdose: Doctors must monitor the patient for evidence of toxicity if an overdose occurs. Treatment of overdose includes monitoring of vital signs as well as observation of the clinical status of the patient.
Storage: Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.